Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?
Cytokinetics, Incorporated (NASDAQ:CYTK) has reported detailed late-stage results that could support an expansion of aficamten into a form of genetic heart disease that currently does not have any approved...






